Loading chat...
MN HF3664
Bill
Status
2/13/2024
Primary Sponsor
Robert Bierman
Click for details
AI Summary
-
Commissioner of human services may provide separate reimbursement to hospitals for biological products used in inpatient cell or gene therapy to treat rare diseases as defined in federal law (21 U.S.C. § 360bb)
-
Separate reimbursement is in addition to the diagnostic related group reimbursement for the inpatient admission or discharge
-
Commissioner shall establish reimbursement rates using the same methodology as outpatient drug administration reimbursement under section 256B.0625, subdivision 13e, paragraph (e)
-
Commissioner may require managed care and county-based purchasing plans to comply with separate reimbursement requirements for medical assistance enrollees at rates meeting or exceeding the commissioner-established level
-
Effective date: January 1, 2025
Legislative Description
Commissioner of human services authorized to provide separate reimbursement for biological products provided in the inpatient hospital setting as part of cell or gene therapy to treat rare diseases.
Last Action
Author added Hemmingsen-Jaeger
3/18/2024